On The Horizon | malecare.org

Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]

By Malecare|2016-04-28T16:08:19-04:00April 28th, 2016|Advanced Prostate Cancer, Clinical Trials & Research, Drugs & Treatments, On The Horizon, survival, Survival, Uncategorized|2 Comments

More From ASCO GU 2016 – ExoDx™ Prostate(IntelliScore): A More Precise, Genetically Informed Prostate Cancer Test from a Simple Urine Sample

The constant hope and conversation of late has surrounded what is referred to as a liquid biopsy. The hope and goal is to no longer need to have an invasive needle biopsy to diagnose and stage prostate cancer. Biopsies are not accurate because there are too many false negatives, they only evaluate the actual tissue [...]

By Malecare|2023-07-08T15:57:45-04:00March 10th, 2016|Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, Disparities, genetics, Genetics and Geonomics, On The Horizon, prognostic tools, Screening, Uncategorized|0 Comments

CTC Heterogeneity Predicts Prostate Cancer Drug Sensitivity

This afternoon I am off to the American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco. There has already been some information leaking to the media about some of the presentations that will be going on at the conference. One such “leak” is about findings from Memorial Sloan Kettering Cancer Center [...]

By Malecare|2017-10-19T10:46:41-04:00January 6th, 2016|Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, CTCs, On The Horizon, prognostic tools, Research, Uncategorized, Understanding Advanced Prostate Cancer|0 Comments

On The Horizon – Tests That Can Inform Us If A Drug Will Work Before We Take The Drug

We have become very fortunate over the last 6 years because our arsenal of potential drugs to treat advanced, metastatic prostate cancer has grown. All of our new drugs extend life and most offer palliation of pain. As I have discussed in prior posts we are still in a quandary about how best to sequence [...]

By Malecare|2017-10-19T10:46:49-04:00November 12th, 2015|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, CTCs, Drugs & Treatments, Enzalutamide (MDV-3100), On The Horizon, prognostic tools, Research, taxanes, Uncategorized, Xtandi, Zytiga|0 Comments

On The Horizon – Tasquinimod – Immunotherapy & An Anti-Angiogenic Agent

In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 [...]

By Malecare|2020-02-04T11:45:03-05:00April 9th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, survival, Tasquinimod (TASQ), Uncategorized|1 Comment